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Abstract
© 2016,  Springer  Science+Business  Media  New  York.In  this  work,  we  studied  molecular-
biological  factors  leading  to  cervical  cancer.  The  clinicopathologic  characteristics  and
immunohistochemical features of 185 patients with cervical pathologies associated with human
papillomavirus  infection  were  examined.  Immunohistochemical  features  analyzed  included
histone deacetylases (HDAC1, HDAC2) and DNA methyltransferases (DNMT1, DNMT2). Strong
correlations of these factors with cervical pathologies including malignancies were identified.
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